Sanofi flunks Parkinson's Phase II, axes handful of mid-stage programs in Q4 earnings

Biogen isn’t the only one hitting roadblocks in Parkinson’s.

Two days after the big biotech revealed in year-end earnings that they cut a Phase II program for the neurodegenerative condition, Sanofi axed their own Phase II Parkinson’s drug in its earnings announcement. The trial failed at the end of January, they said, although they will continue developing the compound, known as venglustat, in a handful of rare diseases.